Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harish Puttagunta

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|December 25, 2015
Peritoneal Dialysis for Heart FailureHarish Puttagunta, Stephen G Holt
Nephrology (Carlton, Vic.)|December 23, 2016
Mesorhizobium peritonitis: The first reported caseAnoushka Krishnan, Edward Raby, Harish Puttagunta, et al.
Frontiers in Medicine|March 11, 2022
mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant RecipientsReece Jefferies, Harish Puttagunta, Anoushka Krishnan, et al.
Heart, Lung & Circulation|September 5, 2025
Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary HospitalNick S R Lan, Ben McFadden, Andrew Johnson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|December 25, 2015
Peritoneal Dialysis for Heart FailureHarish Puttagunta, Stephen G Holt
Nephrology (Carlton, Vic.)|December 23, 2016
Mesorhizobium peritonitis: The first reported caseAnoushka Krishnan, Edward Raby, Harish Puttagunta, et al.
Frontiers in Medicine|March 11, 2022
mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant RecipientsReece Jefferies, Harish Puttagunta, Anoushka Krishnan, et al.
Heart, Lung & Circulation|September 5, 2025
Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary HospitalNick S R Lan, Ben McFadden, Andrew Johnson, et al.
Pageof 1